1.Hirano T Yasukawa K Harada H et al.

Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin.

Nature. 324: 73-762.Garbers C Heink S Korn T Rose-John S

Interleukin-6: designing specific therapeutics for a complex cytokine.

Nat Rev Drug Discov. 17: 395-4123.Heinrich PC Castell JV Andus T

Interleukin-6 and the acute phase response.

Biochem J. 265: 621-6364.

Activation of interleukin-6 gene expression through the NF-κB transcription factor.

Mol Cell Biol. 10: 2327-23345.Shimizu H Mitomo K Watanabe T Okamoto S Yamamoto K

Involvement of a NF-κB-like transcription factor in the activation of the interleukin-6 gene by inflammatory lymphokines.

Mol Cell Biol. 10: 561-5686.Ray A Tatter SB May LT Sehgal PB

Activation of the human “β2-interferon/hepatocyte-stimulating factor/interleukin 6” promoter by cytokines, viruses, and second messenger agonists.

Proc Natl Acad Sci USA. 85: 6701-67057.Matsusaka T Fujikawa K Nishio Y et al.

Transcription factors NF-IL6 and NF-κB synergistically activate transcription of the inflammatory cytokines, interleukin 6 and interleukin 8.

Proc Natl Acad Sci USA. 90: 10193-101978.

HIF1α and metabolic reprogramming in inflammation.

J Clin Invest. 126: 3699-37079.Fong Y Moldawer LL Marano M et al.

Endotoxemia elicits increased circulating β2-IFN/IL-6 in man.

J Immunol. 142: 2321-232410.Palsson-McDermott EM O'Neill LA

The Warburg effect then and now: from cancer to inflammatory diseases.

BioEssays. 35: 965-97311.Kohase M Henriksen-DeStefano D May LT Vilcek J Sehgal PB

Induction of β2-interferon by tumor necrosis factor: a homeostatic mechanism in the control of cell proliferation.

Cell. 45: 659-66612.Kohase M May LT Tamm I Vilcek J Sehgal PB

A cytokine network in human diploid fibroblasts: interactions of β-interferons, tumor necrosis factor, platelet-derived growth factor, and interleukin-1.

Mol Cell Biol. 7: 273-28013.Sehgal PB Helfgott DC Santhanam U et al.

Regulation of the acute phase and immune responses in viral disease. Enhanced expression of the β2-interferon/hepatocyte-stimulating factor/interleukin 6 gene in virus-infected human fibroblasts.

J Exp Med. 167: 1951-195614.Taga T Hibi M Hirata Y et al.

Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130.

Cell. 58: 573-58115.Yamasaki K Taga T Hirata Y et al.

Cloning and expression of the human interleukin-6 (BSF-2/IFN β2) receptor.

Science. 241: 825-82816.Gauldie J Richards C Harnish D Lansdorp P Baumann H

Interferon β2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells.

Proc Natl Acad Sci USA. 84: 7251-725517.Hibi M Murakami M Saito M Hirano T Taga T Kishimoto T

Molecular cloning and expression of an IL-6 signal transducer, gp130.

Cell. 63: 1149-115718.Oberg HH Wesch D Grüssel S Rose-John S Kabelitz D

Differential expression of CD126 and CD130 mediates different STAT-3 phosphorylation in CD4+CD25- and CD25high regulatory T cells.

Int Immunol. 18: 555-56319.Riethmueller S Somasundaram P Ehlers JC et al.

Proteolytic origin of the soluble human IL-6R in vivo and a decisive role of N-glycosylation.

PLoS Biol. 15e200008020.

Soluble receptors for cytokines and growth factors: generation and biological function.

Biochem J. 300: 281-29021.

Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer.

Nat Rev Immunol. 18: 773-78922.Heink S Yogev N Garbers C et al.

Trans-presentation of IL-6 by dendritic cells is required for the priming of pathogenic TH17 cells.

Nat Immunol. 18: 74-8523.Jostock T Müllberg J Ozbek S et al.

Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses.

Eur J Biochem. 268: 160-16724.Yousif AS Ronsard L Shah P et al.

The persistence of interleukin-6 is regulated by a blood buffer system derived from dendritic cells.

Immunity. 25.

Cytokines as therapeutic drugs.

J Interferon Cytokine Res. 22: 505-51626.

IL-6: from its discovery to clinical applications.

Int Immunol. 22: 347-35227.Higuchi T Nakanishi T Takada K et al.

A case of multicentric Castleman's disease having lung lesion successfully treated with humanized anti-interleukin-6 receptor antibody, tocilizumab.

J Korean Med Sci. 25: 1364-136728.Tanaka T Narazaki M Kishimoto T

Interleukin (IL-6) immunotherapy.

Cold Spring Harb Perspect Biol. 10a02845629.European Medicines Agency

RoActemra: Summary of product characteristics.

30.Rose-John S Winthrop K Calabrese L

The role of IL-6 in host defence against infections: immunobiology and clinical implications.

Nat Rev Rheumatol. 13: 399-40931.Klein B Lu ZY Gaillard JP Harousseau JL Bataille R

Inhibiting IL-6 in human multiple myeloma.

Curr Top Microbiol Immunol. 182: 237-24432.Klein B Wijdenes J Zhang XG et al.

Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia.

Blood. 78: 1198-120433.Boulanger MJ Chow DC Brevnova EE Garcia KC

Hexameric structure and assembly of the interleukin-6/IL-6 α-receptor/gp130 complex.

Science. 300: 2101-210434.Skiniotis G Boulanger MJ Garcia KC Walz T

Signaling conformations of the tall cytokine receptor gp130 when in complex with IL-6 and IL-6 receptor.

Nat Struct Mol Biol. 12: 545-55135.Garbers C Hermanns HM Schaper F et al.

Plasticity and cross-talk of interleukin 6-type cytokines.

Cytokine Growth Factor Rev. 23: 85-9736.Taga T Narazaki M Yasukawa K et al.

Functional inhibition of hematopoietic and neurotrophic cytokines by blocking the interleukin 6 signal transducer gp130.

Proc Natl Acad Sci USA. 89: 10998-1100137.Hirota H Chen J Betz UA et al.

Loss of a gp130 cardiac muscle cell survival pathway is a critical event in the onset of heart failure during biomechanical stress.

Cell. 97: 189-19838.Yoshida K Taga T Saito M et al.

Targeted disruption of gp130, a common signal transducer for the interleukin 6 family of cytokines, leads to myocardial and hematological disorders.

Proc Natl Acad Sci USA. 93: 407-41139.

JAK and STAT signaling molecules in immunoregulation and immune-mediated disease.

Immunity. 36: 542-55040.Guschin D Rogers N Briscoe J et al.

A major role for the protein tyrosine kinase JAK1 in the JAK/STAT signal transduction pathway in response to interleukin-6.

EMBO J. 14: 1421-142941.Rodig SJ Meraz MA White JM et al.

Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the JAKS in cytokine-induced biologic responses.

Cell. 93: 373-38342.Schwartz DM Kanno Y Villarino A Ward M Gadina M O'Shea JJ

JAK inhibition as a therapeutic strategy for immune and inflammatory diseases.

Nat Rev Drug Discov. 16: 843-86243.Van Rompaey L Galien R van der Aar EM et al.

Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases.

J Immunol. 191: 3568-357744.Genovese MC Smolen JS Weinblatt ME et al.

Efficacy and safety of ABT-494, a selective JAK-1 Inhibitor, in a phase IIB study in patients with rheumatoid arthritis and an inadequate response to methotrexate.

Arthritis Rheumatol. 68: 2857-286645.Kremer JM Emery P Camp HS et al.

A phase IIB study of ABT-494, a selective JAK-1 inhibitor, in patients with rheumatoid arthritis and an inadequate response to anti-tumor necrosis factor therapy.

Arthritis Rheumatol. 68: 2867-287746.Rubbert-Roth A Enejosa J Pangan AL et al.

Trial of upadacitinib or abatacept in rheumatoid arthritis.

N Engl J Med. 383: 1511-152147.van Vollenhoven RF Fleischmann R Cohen S et al.

Tofacitinib or adalimumab versus placebo in rheumatoid arthritis.

N Engl J Med. 367: 508-51948.O'Shea JJ Gadina M Schreiber RD

Cytokine signaling in 2002: new surprises in the JAK/STAT pathway.

Cell. 109: S121-S13149.Miklossy G Hilliard TS Turkson J

Therapeutic modulators of STAT signalling for human diseases.

Nat Rev Drug Discov. 12: 611-62950.German Clinical Trials Register

A multi-centre, exploratory trial to assess the mechanisms of molecular activity, safety and tolerability of one dose level of FE 999301 by intravenous infusions in patients with active inflammatory bowel disease (IBD).

51.Jones SA Scheller J Rose-John S

Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling.

J Clin Invest. 121: 3375-338352.Scheller J Chalaris A Schmidt-Arras D Rose-John S

The pro- and anti-inflammatory properties of the cytokine interleukin-6.

Biochim Biophys Acta. 1813: 878-88853.Bergmann J Müller M Baumann N et al.

IL-6 trans-signaling is essential for the development of hepatocellular carcinoma in mice.

Hepatology. 65: 89-10354.Rabe B Chalaris A May U et al.

Transgenic blockade of interleukin 6 transsignaling abrogates inflammation.

Blood. 111: 1021-102855.Kellum JA Pike F Yealy DM Huang DT Shapiro NI Angus DC

Relationship between alternative resuscitation strategies, host response and injury biomarkers, and outcome in septic shock: analysis of the protocol-based care for early septic shock study.

Crit Care Med. 45: 438-44556.Molano Franco D Arevalo-Rodriguez I Roqué i Figuls M Montero Oleas NG Nuvials X Zamora J

Plasma interleukin-6 concentration for the diagnosis of sepsis in critically ill adults.

Cochrane Database Syst Rev. 4CD01181157.Pou KM Massaro JM Hoffmann U et al.

Visceral and subcutaneous adipose tissue volumes are cross-sectionally related to markers of inflammation and oxidative stress: the Framingham Heart Study.

Circulation. 116: 1234-124158.Roytblat L Rachinsky M Fisher A et al.

Raised interleukin-6 levels in obese patients.

Obes Res. 8: 673-67559.

Signalling role of adipose tissue: adipokines and inflammation in obesity.

Biochem Soc Trans. 33: 1078-108160.Nilsonne G Lekander M Åkerstedt T Axelsson J Ingre M

Diurnal variation of circulating interleukin-6 in humans: a meta-analysis.

PLoS One. 11e016579961.Keustermans GC Hoeks SB Meerding JM Prakken BJ de Jager W

Cytokine assays: an assessment of the preparation and treatment of blood and tissue samples.

Methods. 61: 10-1762.Riches P Gooding R Millar BC Rowbottom AW

Influence of collection and separation of blood samples on plasma IL-1, IL-6 and TNF-α concentrations.

J Immunol Methods. 153: 125-13163.

Measurement of cytokines in clinical samples using immunoassays: problems and pitfalls.

Crit Rev Clin Lab Sci. 37: 131-18264.Waage A Brandtzaeg P Halstensen A Kierulf P Espevik T

The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin 6, interleukin 1, and fatal outcome.

J Exp Med. 169: 333-33865.Pott GB Chan ED Dinarello CA Shapiro L

α-1-Antitrypsin is an endogenous inhibitor of proinflammatory cytokine production in whole blood.

J Leukoc Biol. 85: 886-89566.Leisman DE Ronner L Pinotti R et al.

Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes.

Lancet Respir Med. 8: 1233-124467.Sinha P Matthay MA Calfee CS

Is a “cytokine storm” relevant to COVID-19?.

JAMA Intern Med. 180: 1152-115468.Hedrick TL Murray BP Hagan RS Mock JR

COVID-19: clean up on IL-6.

Am J Respir Cell Mol Biol. 63: 541-54369.Leisman DE Deutschman CS Legrand M

Facing COVID-19 in the ICU: vascular dysfunction, thrombosis, and dysregulated inflammation.

Intensive Care Med. 46: 1105-110870.

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.

Lancet. 395: 1054-106271.

Dysregulation of immune response in patients with COVID-19 in Wuhan, China.

Clin Infect Dis. 71: 762-76872.

Clinical and immunological features of severe and moderate coronavirus disease 2019.

J Clin Invest. 130: 2620-262973.

Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China.

JAMA Intern Med. 180: 934-94374.Zhang B Zhou X Zhu C et al.

Immune phenotyping based on the neutrophil-to-lymphocyte ratio and IgG level predicts disease severity and outcome for patients with COVID-19.

Front Mol Biosci. 7: 15775.Cai Q Huang D Ou P et al.

COVID-19 in a designated infectious diseases hospital outside Hubei Province, China.

Allergy. 75: 1742-175276.Diao B Wang C Tan Y et al.

Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19).

Front Immunol. 11: 82777.

Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19.

J Med Virol. 92: 791-79678.Ruan Q Yang K Wang W Jiang L Song J

Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China.

Intensive Care Med. 46: 846-84879.Wang Z Yang B Li Q Wen L Zhang R

Clinical features of 69 cases with coronavirus disease 2019 in Wuhan, China.

Clin Infect Dis. 71: 769-77780.Fan H Zhang L Huang B et al.

Retrospective analysis of clinical features in 101 death cases with COVID-19.

medRxiv. () 81.

Virologic and clinical characteristics for prognosis of severe COVID-19: a retrospective observational study in Wuhan, China.

medRxiv. () 82.Huang Y Yang R Xu Y Gong P

Clinical characteristics of 36 non-survivors with COVID-19 in Wuhan, China.

medRxiv. () 83.Liu T Zhang J Yang Y et al.

The role of interleukin-6 in monitoring severe case of coronavirus disease 2019.

EMBO Mol Med. 12e1242184.

Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP).

medRxiv. () 85.Xu Y Li Y-r Zeng Q et al.

Clinical characteristics of SARS-CoV-2 pneumonia compared to controls in Chinese Han population.

medRxiv. () 86.Zhang B Zhou X Qiu Y et al.

Clinical characteristics of 82 death cases with COVID-19.

medRxiv. 87.Zhang H Wang X Fu Z et al.

Potential factors for prediction of disease severity of COVID-19 patients.

medRxiv. () 88.

Management of COVID-19 respiratory distress.

JAMA. 323: 2329-233089.Tobin MJ Laghi F Jubran A

Caution about early intubation and mechanical ventilation in COVID-19.

Ann Intensive Care. 10: 7890.Matthay MA Zemans RL Zimmerman GA et al.

Acute respiratory distress syndrome.

Nat Rev Dis Primers. 5: 1891.Brower RG Matthay MA Morris A Schoenfeld D Thompson T Wheeler A

Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome.

N Engl J Med. 342: 1301-130892.Calfee CS Delucchi K Parsons PE Thompson BT Ware LB Matthay MA

Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials.

Lancet Respir Med. 2: 611-62093.Wiedemann HP Wheeler AP Bernard GR et al.

Comparison of two fluid-management strategies in acute lung injury.

N Engl J Med. 354: 2564-257594.Alladina JW Levy SD Hibbert KA et al.

Plasma concentrations of soluble suppression of tumorigenicity-2 and interleukin-6 are predictive of successful liberation from mechanical ventilation in patients with the acute respiratory distress syndrome.

Crit Care Med. 44: 1735-174395.Brower RG Lanken PN MacIntyre N et al.

Higher versus lower positive end-expiratory pressures in patients with the acute respiratory distress syndrome.

N Engl J Med. 351: 327-33696.Sinha P Delucchi KL McAuley DF O'Kane CM Matthay MA Calfee CS

Development and validation of parsimonious algorithms to classify acute respiratory distress syndrome phenotypes: a secondary analysis of randomised controlled trials.

Lancet Respir Med. 8: 247-25797.Sinha P Delucchi KL Thompson BT McAuley DF Matthay MA Calfee CS

Latent class analysis of ARDS subphenotypes: a secondary analysis of the statins for acutely injured lungs from sepsis (SAILS) study.

Intensive Care Med. 44: 1859-186998.Del Valle DM Kim-Schulze S Huang HH et al.

An inflammatory cytokine signature predicts COVID-19 severity and survival.

Nat Med. 26: 1636-164399.Gadotti AC de Castro Deus M Telles JP et al.

IFN-γ is an independent risk factor associated with mortality in patients with moderate and severe COVID-19 infection.

Virus Res. 289198171100.Hadjadj J Yatim N Barnabei L et al.

Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients.

Science. 369: 718-724101.McElvaney OJ McEvoy NL McElvaney OF et al.

Characterization of the inflammatory response to severe COVID-19 illness.

Am J Respir Crit Care Med. 202: 812-821102.Pierce CA Preston-Hurlburt P Dai Y et al.

Immune responses to SARS-CoV-2 infection in hospitalized pediatric and adult patients.

Sci Transl Med. 12eabd5487103.Remy KE Mazer M Striker DA et al.

Severe immunosuppression and not a cytokine storm characterizes COVID-19 infections.

JCI Insight. 5140329104.Sinha P Calfee CS Cherian S et al.

Prevalence of phenotypes of acute respiratory distress syndrome in critically ill patients with COVID-19: a prospective observational study.

Lancet Respir Med. 8: 1209-1218105.Wilson JG Simpson LJ Ferreira AM et al.

Cytokine profile in plasma of severe COVID-19 does not differ from ARDS and sepsis.

JCI Insight. 5140289106.Abcejo AS Andrejko KM Raj NR Deutschman CS

Failed interleukin-6 signal transduction in murine sepsis: attenuation of hepatic glycoprotein 130 phosphorylation.

Crit Care Med. 37: 1729-1734107.Biran N Ip A Ahn J et al.

Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study.

Lancet Rheumatol. 2: e603-e612108.Guaraldi G Meschiari M Cozzi-Lepri A et al.

Tocilizumab in patients with severe COVID-19: a retrospective cohort study.

Lancet Rheumatol. 2: e474-e484109.Gupta S Wang W Hayek SS et al.

Association between early treatment with tocilizumab and mortality among critically ill patients with COVID-19.

JAMA Intern Med. 181: 41-51110.

Time to reassess tocilizumab's role in COVID-19 pneumonia.

JAMA Intern Med. 181: 12-15111.Somers EC Eschenauer GA Troost JP et al.

Tocilizumab for treatment of mechanically ventilated patients with COVID-19.

Clin Infect Dis. ()112.Hermine O Mariette X Tharaux PL et al.

Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial.

JAMA Intern Med. 181: 32-40113.Salvarani C Dolci G Massari M et al.

Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: a randomized clinical trial.

JAMA Intern Med. 181: 24-31114.Stone JH Frigault MJ Serling-Boyd NJ et al.

Efficacy of tocilizumab in patients hospitalized with COVID-19.

N Engl J Med. 383: 2333-2344115.

Roche provides an update on the phase III COVACTA trial of Actemra/RoActemra in hospitalised patients with severe COVID-19 associated pneumonia.

116.

Roche's phase III EMPACTA study showed Actemra/RoActemra reduced the likelihood of needing mechanical ventilation in hospitalised patients with COVID-19 associated pneumonia.

117.

US trial investigating sarilumab for COVID-19 stopped.

118.Veiga VC Prats JAGG Farias DLC et al.

Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial.

BMJ. 372: n84119.Perlmutter DH May LT Sehgal PB

Interferon β2/interleukin 6 modulates synthesis of α1-antitrypsin in human mononuclear phagocytes and in human hepatoma cells.

J Clin Invest. 84: 138-144120.Carrell RW Jeppsson JO Laurell CB et al.

Structure and variation of human α1-antitrypsin.

Nature. 298: 329-334121.Lee CT Fein AM Lippmann M Holtzman H Kimbel P Weinbaum G

Elastolytic activity in pulmonary lavage fluid from patients with adult respiratory-distress syndrome.

N Engl J Med. 304: 192-196122.

The role of neutrophil elastase in chronic inflammation.